NCT06539559 2024-08-06Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Not yet recruiting60 enrolled